EndoResFellow said:Read four things before the headline number.
Thank you for spelling out the reasoning rather than just the conclusion. I will report back once I have actually tried it.
From the other side of the consultation, briefly.
TrialTracker_MD said:...regarding the trial evidence...
I think this is an underappreciated point. To expand on it with some data:
A recent meta-analysis of 12 RCTs (n=8,400) found that the trial evidence was associated with a significant effect size across diverse patient populations[1].
The NNT was 8, which is comparable to metformin for T2DM prevention. That's a strong clinical argument for this approach.
VendorMark said:The gap between trial results and real-world results is consistent and it is not fraud.
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.
A recent PSM study of 25,000 GLP-1 users vs matched controls showed reduced all-cause mortality (HR 0.81) over 5 years of follow-up[1].
These results complement the RCT data and suggest the benefits translate to real-world populations.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsTrialTracker_MD said:ClinicalTrials.gov GLP-1 trial tracker — updated weekly Pinned because it affects plans people have already made, not because it is dramatic.
Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to:
The the trial evidence meta-analysis shows a pooled RR of 0.73 (95% CI 0.66-0.83), I²=31%. This is a robust and consistent effect.